Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - INTEVAC INC | d617696d8k.htm |
Exhibit 99.1
|
3560 Bassett Street, Santa Clara CA 95054 |
| Jeff Andreson | Claire McAdams | |||
| Chief Financial Officer | Investor Relations | |||
| (408) 986-9888 | (530) 265-9899 |
INTEVAC ANNOUNCES THIRD QUARTER 2013 FINANCIAL RESULTS
Santa Clara, Calif.—October 28, 2013—Intevac, Inc. (Nasdaq: IVAC) today reported financial results for the quarter and nine months ended September 28, 2013.
“We continued to build momentum in our Photonics business during the third quarter, with backlog increasing to $51 million,” commented Wendell Blonigan, president and chief executive officer. “In our hard drive equipment business, we continue to focus on maintaining our technology leadership position in the industry, working closely with our customers to align our technology roadmap with the expected media capacity needs over the next several years.
“On the equipment diversification front, we recently received an order from a new Tier 1 customer for a high-throughput thin film deposition system to be used in the manufacturing of crystalline silicon solar cells. This system is capable of depositing a variety of films, including critical metal films required for advanced silicon solar cell architectures. We are pleased that this order builds upon our recent success in solar ion implant, by adding a new application and a new Tier 1 customer for the company. In the meantime, we continue to prudently manage the level of expenditures as we manage through the current environment in the solar industry.”
| ($ Millions, except per share amounts) | Q3 2013 | Q3 2012 | ||||||||||||||
| GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||
| Net Revenues |
$ | 19.1 | $ | 19.1 | $ | 16.8 | $ | 16.8 | ||||||||
| Operating Loss |
$ | (3.0 | ) | $ | (3.0 | ) | $ | (11.0 | ) | $ | (8.0 | ) | ||||
| Net Loss |
$ | (2.7 | ) | $ | (2.7 | ) | $ | (8.0 | ) | $ | (6.0 | ) | ||||
| Net Loss per Share |
$ | (0.11 | ) | $ | (0.11 | ) | $ | (0.34 | ) | $ | (0.26 | ) | ||||
| Nine Months Ended September 28, 2013 |
Nine Months Ended September 29, 2012 |
|||||||||||||||
| GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||
| Net Revenues |
$ | 49.1 | $ | 49.1 | $ | 65.9 | $ | 65.9 | ||||||||
| Operating Loss |
$ | (19.0 | ) | $ | (18.0 | ) | $ | (18.6 | ) | $ | (17.8 | ) | ||||
| Net Loss |
$ | (17.4 | ) | $ | (16.5 | ) | $ | (12.7 | ) | $ | (12.4 | ) | ||||
| Net Loss per Share |
$ | (0.73 | ) | $ | (0.69 | ) | $ | (0.54 | ) | $ | (0.53 | ) | ||||
Third Quarter 2013 Summary
The net loss for the quarter was $2.7 million, or $0.11 per share, compared to a net loss of $8.0 million, or $0.34 per share, in the third quarter of 2012.
Revenues were $19.1 million, including $11.8 million of Equipment revenues and Photonics revenues of $7.4 million. Equipment revenues consisted of one 200 Lean system, upgrades, spares and service. Photonics revenues included $3.1 million of research and development contracts. In the third quarter of 2012, revenues were $16.8 million, including $7.4 million of Equipment revenues and Photonics revenues of $9.4 million, which included $5.2 million of research and development contracts.
Equipment gross margin increased to 39.7% compared to 35.6% in the third quarter of 2012 as a result of higher revenue volume and a higher mix of upgrades. Photonics gross margin was 30.3% compared to 32.8% in the third quarter of 2012, reflecting lower margins on our technology development programs. Consolidated gross margin was 36.1%, compared to 34.1% in the third quarter of 2012. Operating expenses were $9.9 million, compared to $16.7 million in the third quarter of 2012, down primarily as a result of our global cost reduction program. Operating expenses in the third quarter of 2012 had also included a $3.0 million bad debt charge.
Order backlog totaled $70.7 million on September 28, 2013, compared to $77.6 million on June 29, 2013 and $40.0 million on September 29, 2012. Backlog as of September 28, 2013 includes two 200 Lean systems as compared to three 200 Lean systems on June 29, 2013. Backlog at September 29, 2012 did not include any 200 Lean systems.
The company ended the quarter with $85.7 million of cash and investments and $123.7 million in tangible book value.
First Nine Months 2013 Summary
The net loss was $17.4 million, or $0.73 per share, compared to a net loss of $12.7 million, or $0.54 per share, for the first nine months of 2012. The non-GAAP net loss, which excludes a $0.7 million restructuring charge and a $0.2 million divestiture loss, was $16.5 million or $0.69 per share. This compares to the first nine months 2012 non-GAAP net loss of $12.4 million, or $0.53 per share, which excludes a $3.0 million bad debt charge and a $2.2 million divestiture gain.
Revenues were $49.1 million, including $26.3 million of Equipment revenues and Photonics revenues of $22.8 million, compared to revenues of $65.9 million, including $43.2 million of Equipment revenues and Photonics revenues of $22.8 million, for the first nine months of 2012.
Equipment gross margin was 27.4%, compared to 44.7% in the first nine months of 2012, primarily due to the lower level of revenue from upgrades, lower factory absorption, a refurbishment provision for a solar evaluation system, and the lower system margin on the first solar implant ENERGi system recognized for revenue. Photonics gross margin was 30.8% compared to 33.1% in the first nine months of 2012, reflecting lower margins on our technology development programs. Consolidated gross margin was 29.0%, compared to 40.7% in the first nine months of 2012.
Operating expenses were $33.0 million, which includes approximately $0.4 million in severance costs related to our global cost reduction plan, and were down 31% from $47.7 million in the first nine months of 2012. The operating loss of $19.0 million included a total of $0.7 million of restructuring charges and a $0.2 million loss on the sale of our Raman spectroscopy product line. The operating loss of $18.6 million for the first nine months of 2012 included a $3.0 million bad debt charge, offset inpart by a $2.2 million gain on the sale of our mainframe technology.
Use of Non-GAAP Financial Measures
Intevac’s non-GAAP results exclude the impact of the following, where applicable: (1) restructuring charges; (2) gains or losses on sales of product lines and technology assets; and (3) certain bad debt charges. A reconciliation of the GAAP and non-GAAP results is provided in the financial tables included in this release.
Management uses non-GAAP results to evaluate the company’s operating and financial performance in light of business objectives and for planning purposes. These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies. Intevac believes these measures enhance investors’ ability to review the company’s business from the same perspective as the company’s management and facilitate comparisons of this period’s results with prior periods. The presentation of this additional information should not be considered a substitute for results prepared in accordance with GAAP.
Conference Call Information
The company will discuss its financial results and outlook in a conference call today at 1:30 p.m. PDT (4:30 p.m. EDT). To participate in the teleconference, please call toll-free (877) 334-0811 prior to the start time. For international callers, the dial-in number is (408) 427-3734. You may also listen live via the Internet at the company’s website, www.intevac.com, under the Investors link, or at www.earnings.com. For those unable to attend, these web sites will host an archive of the call. Additionally, a telephone replay of the call will be available for 48 hours beginning today at 7:30 p.m. EDT. You may access the replay by calling (855) 859-2056 or, for international callers, (404) 537-3406, and providing Replay Passcode 76011290.
About Intevac
Intevac was founded in 1991 and has two businesses: Equipment and Photonics.
In our Equipment business, we are a leader in the design, development and manufacturing of high-productivity, vacuum process equipment solutions. Our systems are production-proven for high-volume manufacturing of small substrates with precise thin film properties, such as those required in the hard drive and solar cell markets we currently serve.
In the hard drive industry, our 200 Lean® systems process approximately 60% of all magnetic disk media produced worldwide. In the solar cell manufacturing industry, our LEAN SOLAR™ systems increase the conversion efficiency of silicon solar cells.
In our Photonics business, we are a leader in the development and manufacture of leading-edge, high-sensitivity imaging products and vision systems. Our products primarily address the defense markets.
For more information call 408-986-9888, or visit the company’s website at www.intevac.com.
200 Lean® is a registered trademark and ENERGi™ and LEAN SOLAR™ are trademarks of Intevac, Inc.
Safe Harbor Statement
This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Intevac claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” or “anticipates,” and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: expected delivery of cameras for the Apache program, and ability to maintain technology leadership. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the company’s expectations. These risks include, but are not limited to: oversupply in the media industry, a further slowdown in demand for hard drives, a change in the delivery rate of the cameras for the Apache program and the failure to ship these cameras, each of which could have a material impact on our business, our financial results, and the company’s stock price. These risks and other factors are detailed in the company’s periodic filings with the U.S. Securities and Exchange Commission.
INTEVAC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share amounts)
| Three months ended | Nine months ended | |||||||||||||||
| September 28, 2013 |
September 29, 2012 |
September 28, 2013 |
September 29, 2012 |
|||||||||||||
| Net revenues |
||||||||||||||||
| Equipment |
$ | 11,760 | $ | 7,401 | $ | 26,293 | $ | 43,179 | ||||||||
| Photonics |
7,355 | 9,433 | 22,788 | 22,762 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total net revenues |
19,115 | 16,834 | 49,081 | 65,941 | ||||||||||||
| Gross profit |
6,895 | 5,732 | 14,237 | 26,811 | ||||||||||||
| Gross margin |
||||||||||||||||
| Equipment |
39.7 | % | 35.6 | % | 27.4 | % | 44.7 | % | ||||||||
| Photonics |
30.3 | % | 32.8 | % | 30.8 | % | 33.1 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Consolidated |
36.1 | % | 34.1 | % | 29.0 | % | 40.7 | % | ||||||||
| Operating expenses |
||||||||||||||||
| Research and development |
4,250 | 7,336 | 16,192 | 24,812 | ||||||||||||
| Selling, general and administrative |
5,627 | 6,389 | 16,834 | 19,831 | ||||||||||||
| Bad debt expense |
— | 3,017 | — | 3,017 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
9,877 | 16,742 | 33,026 | 47,660 | ||||||||||||
| Gain (loss) on divestitures |
— | — | (208 | ) | 2,207 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating loss |
(2,982 | ) | (11,010 | ) | (18,997 | ) | (18,642 | ) | ||||||||
| Operating income (loss) |
||||||||||||||||
| Equipment |
(1,423 | ) | (10,298 | ) | (14,607 | ) | (15,493 | ) | ||||||||
| Photonics |
192 | 717 | 254 | (939 | ) | |||||||||||
| Corporate1,2 |
(1,751 | ) | (1,429 | ) | (4,644 | ) | (2,210 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating income (loss) |
(2,982 | ) | (11,010 | ) | (18,997 | ) | (18,642 | ) | ||||||||
| Interest and other income (expense) |
220 | (8 | ) | 392 | 411 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income taxes |
(2,762 | ) | (11,018 | ) | (18,605 | ) | (18,231 | ) | ||||||||
| Benefit for income taxes |
(17 | ) | (3,011 | ) | (1,184 | ) | (5,570 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (2,745 | ) | $ | (8,007 | ) | $ | (17,421 | ) | $ | (12,661 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss per share |
||||||||||||||||
| Basic and Diluted |
$ | (0.11 | ) | $ | (0.34 | ) | $ | (0.73 | ) | $ | (0.54 | ) | ||||
| Weighted average common shares outstanding |
||||||||||||||||
| Basic and Diluted |
23,931 | 23,397 | 23,793 | 23,293 | ||||||||||||
| 1 | Nine months ended September 28, 2013 includes the loss on sale of the Raman spectroscopy product line of $208,000. |
| 2 | Nine months ended September 29, 2012 includes the gain on sale of the mainframe technology of $2.2 million. |
INTEVAC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| September 28, 2013 |
December 31, 2012 |
|||||||
| (Unaudited) | (see Note) | |||||||
| ASSETS |
||||||||
| Current assets |
||||||||
| Cash, cash equivalents and short-term investments |
$ | 65,059 | $ | 64,852 | ||||
| Accounts receivable, net |
16,114 | 19,822 | ||||||
| Inventories |
25,794 | 26,193 | ||||||
| Prepaid expenses and other current assets |
1,750 | 2,120 | ||||||
|
|
|
|
|
|||||
| Total current assets |
108,717 | 112,987 | ||||||
| Long-term investments |
20,661 | 27,317 | ||||||
| Property, plant and equipment, net |
13,065 | 13,426 | ||||||
| Deferred income tax assets |
13,189 | 12,176 | ||||||
| Intangible assets, net |
5,180 | 5,868 | ||||||
| Other long-term assets |
541 | 729 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 161,353 | $ | 172,503 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities |
||||||||
| Accounts payable |
$ | 4,719 | $ | 4,479 | ||||
| Accrued payroll and related liabilities |
5,246 | 4,194 | ||||||
| Deferred income tax liabilities |
1,281 | 1,281 | ||||||
| Other accrued liabilities |
6,111 | 8,489 | ||||||
| Customer advances |
5,862 | 2,193 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
23,219 | 20,636 | ||||||
| Other long-term liabilities |
9,250 | 9,232 | ||||||
| Stockholders’ equity |
||||||||
| Common stock ($0.001 par value) |
24 | 23 | ||||||
| Additional paid in capital |
155,701 | 151,996 | ||||||
| Accumulated other comprehensive income |
733 | 769 | ||||||
| Accumulated deficit |
(27,574 | ) | (10,153 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
128,884 | 142,635 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 161,353 | $ | 172,503 | ||||
|
|
|
|
|
|||||
Note: Amounts as of December 31, 2012 are derived from the December 31, 2012 audited consolidated financial statements.
INTEVAC, INC.
RECONCILIATION OF GAAP TO NON-GAAP RESULTS
(Unaudited, in thousands, except per share amounts)
| Three months ended | Nine months ended | |||||||||||||||
| September 28, 2013 |
September 29, 2012 |
September 28, 2013 |
September 29, 2012 |
|||||||||||||
| Non-GAAP Loss from Operations |
||||||||||||||||
| Reported operating loss (GAAP basis) |
$ | (2,982 | ) | $ | (11,010 | ) | $ | (18,997 | ) | $ | (18,642 | ) | ||||
| Restructuring charges1 |
— | — | 742 | — | ||||||||||||
| Loss on sale of Raman spectroscopy product line2 |
— | — | 208 | — | ||||||||||||
| Gain on sale of mainframe technology3 |
— | — | — | (2,207 | ) | |||||||||||
| Bad debt expense4 |
— | 3,017 | — | 3,017 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Operating Loss |
$ | (2,982 | ) | $ | (7,993 | ) | $ | (18,047 | ) | $ | (17,832 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Net Loss |
||||||||||||||||
| Reported net loss (GAAP basis) |
$ | (2,745 | ) | $ | (8,007 | ) | $ | (17,421 | ) | $ | (12,661 | ) | ||||
| Restructuring charges1 |
— | — | 742 | — | ||||||||||||
| Loss on sale of Raman spectroscopy product line2 |
— | — | 208 | — | ||||||||||||
| Gain on sale of mainframe technology3 |
— | — | — | (2,207 | ) | |||||||||||
| Bad debt expense4 |
— | 3,017 | — | 3,017 | ||||||||||||
| Income tax effect of non-GAAP adjustments5 |
— | (1,056 | ) | (42 | ) | (502 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Net Loss |
$ | (2,745 | ) | $ | (6,046 | ) | $ | (16,513 | ) | $ | (12,353 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Loss Per Diluted Share |
||||||||||||||||
| Reported loss per diluted share (GAAP basis) |
$ | (0.11 | ) | $ | (0.34 | ) | $ | (0.73 | ) | $ | (0.54 | ) | ||||
| Restructuring charges1 |
— | — | 0.03 | — | ||||||||||||
| Loss on sale of Raman spectroscopy product line2 |
— | — | 0.01 | — | ||||||||||||
| Gain on sale of mainframe technology3 |
— | — | — | (0.07 | ) | |||||||||||
| Bad debt expense4 |
— | 0.08 | — | 0.08 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Loss Per Diluted Share |
$ | (0.11 | ) | $ | (0.26 | ) | $ | (0.69 | ) | $ | (0.53 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average number of diluted shares |
23,931 | 23,397 | 23,793 | 23,293 | ||||||||||||
| 1 | Results for the nine months ended September 28, 2013 include severance and other employee-related costs $742,000 related to the restructuring program announced on February 1, 2013. |
| 2 | The nine months ended September 28, 2013 includes the loss on sale of the Raman spectroscopy product line of $208,000. On March 29, 2013, the Company sold certain assets including tangible and intangible assets and divested of certain liabilities which comprised its Raman spectroscopy product line for proceeds of not to exceed $1.5 million of which $500,000 was paid in cash upon closing and up to $1.0 million is in the form of an earnout. Intevac did not recognize the earnout payments upon closing given the uncertainties associated with the achievement of the earnout. |
| 3 | The nine months ended September 29, 2012 includes the gain on sale of the mainframe technology of $2.2 million. On January 6, 2012, the Company sold certain assets including intellectual property and residual assets which comprised its semiconductor mainframe technology for proceeds of $3.0 million. |
| 4 | The three and nine months ended September 29, 2012 includes a write-off of a promissory note from a customer in the amount of $3.0 million due to the insolvency of the customer. |
| 5 | The amount represents the estimated income tax effect of the non-GAAP adjustments. The Company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each specific non-GAAP item. |